Headline
The latest stories from AHA Today.
President Biden announced the federal government will purchase an additional 200 million doses of the two COVID-19 vaccines authorized by the Food and Drug Administration for emergency use.
Inspired by recent examples in sports and a Hamilton show tune, Kenneth Kaufman, managing director and chair of management consultancy KaufmanHall, challenges senior health care leaders to “make 2021 the year of true advancement in diversity, equity, and inclusion.”
The Joint Commission released for comment through Feb. 16 proposed new and revised workplace violence prevention standards for accredited hospitals and critical access hospitals.
The National Institutes of Health has launched an online data portal to collect clinical information on neurological symptoms, complications and outcomes related to COVID-19.
Drug maker Eli Lilly and Company said its neutralizing antibodies cocktail of bamlanivimab and etesevimab combine to significantly reduce hospitalizations and deaths attributed to COVID-19.
Regeneron Pharmaceuticals Inc. announced interim data indicating that its REGEN-COV antibody cocktail could be used as a passive vaccine to prevent COVID-19.
The public health emergency will likely remain in place through 2021, and the administration will give states 60 days’ notice before it decides to terminate the emergency or let it expire.
The Food and Drug Administration reissued emergency use authorizations for 10 systems authorized to decontaminate certain N95 respirators.
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed.
AHA today urged the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and “replace it with a serious effort at drug pricing reform.”